Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Evaluate whether the S&P 500 or total market index better suits your retirement goals, considering risk, fees, and long-term growth.
28,526 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
Offerpad rolls out two internal AI platforms, SCOUT and HENRY, as the company pursues 1,000 quarterly home transactio...
The Federal Trade Commission sent a formal warning to Mortgage Connect over its use of noncompete agreements, citing ...
A small cadre of high-priced stocks stubbornly resist stock splits even as peers embrace them. Here are four names le...
The House Ways and Means Committee plans a June hearing to decide if crypto tax relief should cover more than stablec...
Palantir tumbles about 7% midday as Palo Alto Networks and CrowdStrike hold steadier, raising questions about governm...
Apple stock is trading in the high 300s as traders weigh a possible rally. Here are three catalysts that could push a...
After a quarterly report, Netflix's post-earnings sell-off just highlighted a shift in strategy. This article breaks ...
A seismic shift is unfolding in housing finance: the rental market entered infrastructure era, pushing lenders to red...
Nasdaq's chief executive rose through strategy to the top by embracing risk-taking over risk management. This piece t...
A Reuters briefing this week reignited the debate over Banksy’s anonymity and its effect on art values, prompting a r...
Housing turnover has slipped to multi-decade lows, pushing lenders and agents to rethink pricing. A new framework gui...